Paul Hippenmeyer is an Adjunct Professor in the Management Department at the Robert J. Trulaske Sr. College of Business, University of Missouri - Columbia. Paul was a Business Development Director in the Office of Technology Management at Washington University in St. Louis through July 2020 when he retired from his position. Prior to this position, Paul was a Senior Licensing and Business Development Associate in the Office of Technology Management and Industry Relations at the University of Missouri-Columbia from November 2009 through October 2015. In both positions he was responsible for the evaluation of University generated technologies for patentability/marketability and for licensing those promising technologies to corporate entities. Paul’s focus is on biomedical technologies including therapeutics, devices, biomarkers and diagnostics.
In addition, Paul has 20+ years in the pharma/biotech drug discovery space with senior scientific leadership roles in several therapeutic areas and in technology development. Prior to working at Mizzou, he was Director of Research at Keel Pharmaceuticals in Cambridge, MA; a start-up biotechnology company targeting type 1 diabetes. Paul held several positions at Monsanto, Searle and Pharmacia rising to the position of Science Fellow and Senior Research Advisor in the oncology division where he directed research in new target identification and characterization. Before his entry into the oncology field, he was a project leader for an antiviral drug discovery program and managed an international collaboration in the protease inhibitor field. Prior to antiviral drug discovery, Paul was involved in technology development. He has 20+ peer reviewed publications and review articles as well as several patents. He was an Assistant Vice President of the Association of University Technology Managers (AUTM), responsible for their annual Licensing Survey. Paul continues to teach and advise startups.